|
Video: What is a Stock Split?
|
|
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications. According to our Nurix Therapeutics stock split history records, Nurix Therapeutics has had 0 splits. | |
|
Nurix Therapeutics (NRIX) has 0 splits in our Nurix Therapeutics stock split history database.
Looking at the Nurix Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Nurix Therapeutics shares, starting with a $10,000 purchase of NRIX, presented on a split-history-adjusted basis factoring in the complete Nurix Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/27/2020 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$19.57 |
|
End price/share: |
$12.36 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-36.84% |
|
Average Annual Total Return: |
-11.53% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,316.10 |
|
Years: |
3.75 |
|
|
|
|
|